Interleukin-6 blocker therapies are therapeutic breakthrough in rheumatoid arthritis (RA). The occurrence of tuberculosis - common in our Moroccan endemic context - under Tocilizumab has been rarely described. We report the case of reactivation of pulmonary tuberculosis under IL-6 receptor antagonists in a patient followed for seropositive deforming rheumatoid arthritis. The risk of developing tuberculosis is high in RA either by immunological disorder or by the use of immunosuppressive agents. The occurrence of tuberculosis with Tocilizumab has been rarely described in the literature. The observation of our patient then brings to the literature a new case of reactivation of tuberculosis under inhibitor of IL-6 receptors. Thorough monitoring and tuberculosis screening is required before starting treatment with IL6 inhibitors.